- Report
- November 2023
- 263 Pages
Global
From €4446EUR$4,950USD£3,798GBP
- Report
- May 2023
- 251 Pages
Global
From €3930EUR$4,375USD£3,357GBP
- Report
- August 2023
- 395 Pages
Global
From €3772EUR$4,200USD£3,222GBP
- Report
- June 2022
- 327 Pages
Global
From €3144EUR$3,500USD£2,685GBP
- Report
- December 2024
- 180 Pages
Global
From €4177EUR$4,650USD£3,568GBP
- Report
- August 2024
- 294 Pages
Global
From €3750EUR$4,175USD£3,203GBP
- Report
- August 2025
- 193 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 196 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 197 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 180 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 191 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 199 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- September 2024
- 73 Pages
Asia Pacific
From €2919EUR$3,250USD£2,493GBP
- Report
- December 2023
- 172 Pages
Global
From €2223EUR$2,475USD£1,899GBP
€4446EUR$4,950USD£3,798GBP
- Report
- March 2025
- 120 Pages
Global
From €5344EUR$5,950USD£4,565GBP
- Report
- August 2025
- 194 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 199 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 189 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 197 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2025
- 186 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more